MedTrace Logo

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2023-03-28

No results posted yet for this study

Summary

This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.

Conditions

  • Relapsed/Refractory Advanced Solid Tumors
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • Relapsed/Refractory Myelodysplasia
  • Relapsed/Refractory Myelofibrosis
  • Adenoid Cystic Carcinoma
  • Relapsed/Refractory Mantle Cell Lymphoma
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Refractory Chronic Myelomonocytic Leukemia

Interventions

DRUG

PRT543

PRT543 will be administered orally

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2022-11-16
Completion
2022-11-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03886831 on ClinicalTrials.gov